To view this email as a web page, click here.
Conference Coverage
 
September 16, 2017
Avelumab safety profile is “acceptable”
Immunotherapy improves Merkel cell carcinoma, but questions remain.
Read more
 
ADVERTISEMENT
 
Update: Immunotherapeutic options in advanced melanoma
At EADV, Dr. Simone Ribero reviews the latest data on new treatments for advanced melanoma.
Read more
 
Oral baricitinib instead of topicals for atopic dermatitis?
EADV study shows that this JAK inhibitor is a promising drug candidate in moderate-to-severe AD.
Read more
 
ADVERTISEMENT
Ad description here
 

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.